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he
integrated
US
Public
Health
Emergency
Medical
Countermeasures
Enterprise
(PHEMCE) has made great strides in
strategic preparedness and response
capabilities. There have been numerous advances in planning, biothreat
countermeasure development, licensure,
manufacturing, stockpiling and deployment. Increased biodefense surveillance
capability has dramatically improved,
while new tools and increased awareness have fostered rapid identification of
new potential public health pathogens.
Unfortunately, structural delays in vaccine design, development, manufacture,
clinical testing and licensure processes
remain significant obstacles to an effective national biodefense rapid response
capability. This is particularly true for
the very real threat of “novel pathogens” such as the avian-origin influenzas
H7N9 and H5N1, and new coronaviruses such as hCoV-EMC. Conventional
approaches to vaccine development,
production, clinical testing and licensure are incompatible with the prompt
deployment needed for an effective
public health response. An alternative
approach, proposed here, is to apply
computational vaccine design tools and
rapid production technologies that now
make it possible to engineer vaccines for
novel emerging pathogen and WMD
biowarfare agent countermeasures in
record time. These new tools have the
potential to significantly reduce the
time needed to design string-of-epitope vaccines for previously unknown
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pathogens. The design process—from
genome to gene sequence, ready to insert
in a DNA plasmid—can now be accomplished in less than 24 h. While these
vaccines are by no means “standard,”
the need for innovation in the vaccine
design and production process is great.
Should such vaccines be developed, their
60-d start-to-finish timeline would represent a 2-fold faster response than the
current standard.
The Problem: Delayed Response
to Emerging Infections and
Biowarfare Attacks
According to the Commission on
the Prevention of Weapons of Mass
Destruction (WMD) Proliferation and
Terrorism, medical counter-measures
such as vaccines are critically important
for protecting first-responders and noncombatant (civilian) populations from
the consequences of a bioterror attack.
In 2008, Bob Graham (D-FL) and Jim
Talent (R-MO), chairs of the WMD commission and authors of World at Risk,
reported that the United States was “seriously lacking” in this vital capability.1
The 2009 H1N1 influenza pandemic
highlighted continued weaknesses in the
national preparedness system; as a consequence, Graham and Talent gave US
bio-defense preparedness an “F” in their
follow-up report, published in 2010.2 The
Governmental Accounting Office (GAO)
also reported poor inter-agency coordination on biodefense.3,4 As a result of renewed
emphasis on biodefense, the United States
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A Proposed Solution: Design and
Delivery of “Vaccines on Demand”

Figure 1. Two vaccine development timelines. Top: Traditional Vaccine Development. Bottom:
Proposed “FastVax” timeline for development of “Vaccines on Demand.”

Figure 2. We applied the genome-to-vaccine approach to developing an epitope-based vaccine
for avian H7N9 influenza. The design project started on April 5, 2013 and was completed 20 h later.
For vaccine production, the genome-derived vaccine sequences would be sent by secure email to
a plasmid DNA production facility to manufacture a DNA vaccine (Step 2); following scale-up and
production, the vaccine would be distributed in a microneedle patch or another easy-to-distribute formulation (Step 3/4). *ICS = immunogenic consensus sequences.7

government has expended substantial
resources on protecting the nation against
a potential bioterror attack, creating specialized units for planning and preparedness within the Departments of Health
and Human Services, Defense, Homeland
Security, Agriculture, Commerce and
State.
Vaccine production infrastructure has
also improved due to significant investments by the Federal government. For
example, there are now several federally
subsidized “Advanced Development and
Manufacturing” production facilities

1878

distributed in different regions of the
country that are capable of producing millions of doses of protein-based vaccines.5
Unfortunately, despite these important
advances in the strategic preparedness
of US agencies for biodefense, vaccine
design remains a significant obstacle to
national biodefense. This is particularly
true for the very real threat of as-yetundetermined pathogens for which little
is known about their critical antigenic
determinants and correlates of immunity,
the key parameters used in vaccine design
for conventional pathogens.
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Recent reports6 of a novel H7N9 avian
influenza virus emerging in China have
led to even greater scrutiny of methods
used to respond to infectious disease public health threats and have, in turn, provided for a “live fire” assessment of novel
approaches. In 2009–2010, the FastVax
group began to discuss whether existing
tools and vaccine production platforms
could be used to accelerate the development of vaccines for emerging infectious diseases, as illustrated in Figure 1.
Traditional vaccine development for previously unknown pathogens takes place
on the time scale of years. The accelerated process, as proposed by our group,
would begin with analysis of the genomic
sequence of an emerging pathogen with
immunoinformatics tools, followed by
rapid design of an epitope-based vaccine
containing the most immunogenic components, using an integrated in silico
approach illustrated in Figure 2. Once
the vaccine is designed, production and
testing would involve a four-step process
undertaken by the FastVax consortium
arrangement, as described below.
Several constraints affecting the proposed approach bear mentioning; each of
these is addressed in turn.
T cell epitope-based vaccines provide the minimal, essential information
required for protective immunity T cell
epitopes are critical mediators of cellular immunity. They are derived from a
pathogen’s proteins via two pathways:
(1) intracellular proteins are processed,
and their constituent peptides are loaded
onto major histocompatability complex (MHC) class I molecules; and (2)
exogenous proteins are processed in the
proteolytic compartment, and their constituent peptides are loaded onto MHC
class II molecules. MHC class I and class
II-peptide complexes are then transported
to the surface of an APC, where they are
exposed to interrogation by passing T cells
(CD8 + and CD4 + T cells, respectively).
From these different antigen processing
and presentation pathways, two distinct
T cell responses are generated: (1) a CD8 +
cytotoxic T lymphocyte immune response
that is critical for pathogen clearance, and
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(2) a CD4 + T helper immune response
that is essential for robust and sustained
antibody and cytotoxic T lymphocyte
responses. After initial exposure to pathogen, memory T cells are established that
respond more rapidly and efficiently upon
subsequent exposure.
Because epitopes provide the essential
information needed to trigger a protective
immune response, epitope-based vaccines
can be developed to recreate this response.
Given the lengthy process that is usually
associated with the development of killed,
live-attenuated and whole-subunit vaccine
approaches, an epitope-based strategy is
one rational alternative, particularly when
no vaccine exists and an emerging pathogen threatens human health on a global
scale.
T cell epitopes do not protect against
infection; however, they may protect
against disease
There is published evidence demonstrating that epitope-based vaccines can
be protective. Vaccination with peptide
epitopes stimulates protective immune
responses in a range of animal models, including complete protection of
BALB/c mice against RSV challenge,8
partial protection of BALB/c mice against
Plasmodium yoelii sporozoite challenge,9
partial protection of BALB/c and CBA
mice against encephalitis following intracerebral challenge with a lethal dose of
measles virus,10 complete protection of
BALB/c mice from intraperitoneal HSV
challenge,11 high degree of protection
of BALB/c mice against infection with
malaria or influenza A virus,12 full protection of sheep against BLV,13 and full
protection of horses against West Nile
Virus.14 Furthermore, experts are generally in agreement that cross-reactive T cell
epitopes were responsible for the limited
morbidity and mortality associated with
pandemic H1N1 in 2009.15-17 The absence
of T cell epitopes may be contributing to
the rapid spread and significant mortality
rate of H7N9 in China.18 T cell epitoperelated immune responses appear to be
critically important for reducing morbidity and mortality in human infectious
disease.19
No “Fast Track” to vaccine-on-demand
approval is currently possible under existing FDA regulations
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Epitope-driven vaccines offer distinct advantages that should contribute
to a reconsideration of the current vaccine approval process for emergency use.
Multiple epitopes derived from more than
one antigen can be packaged together in a
single cassette. In this way, a broad-based
immune response directed against multiple antigenic proteins associated with
the pathogen can be elicited without the
need to manufacture and administer large
quantities of protein, much of which will
be immunologically irrelevant or potentially even reactogenic. This is likely to
reduce formulation challenges, decrease
cost and accelerate the development process. The use of epitopes also helps to
mitigate potential safety concerns stemming from the use of intact recombinant
proteins that may have undesired biological activity (e.g., enzymes, immunomodulators, cross-reactivity, toxins, etc.).
For example, the NP protein of Lassa has
been associated with immune-suppressive
activity.20 Genome sequencing, immunoinformatics tools and the epitope-driven
approach now make it possible to develop
vaccines on demand in response to emerging pathogens.
A Four-Step Process to Design
and Deliver “Vaccines On
Demand”
Step one: Genome-derived, epitopedriven vaccine strategy (GD-EDV). The
first step to making “faster vaccines” is
to design vaccine immunogens directly
from pathogen genomes.21 For example,
for emerging influenza strains, the vaccine “payload” is constructed in silico
using the pathogen genome sequence provided by the World Health Organization
(WHO) or posted on GISAID (http://
platform.gisaid.org/). T cell epitopemapping algorithms that are integrated
in a “vaccine design toolkit” developed by
Martin and De Groot are applied to the
genome sequences.22 These tools derive
and concatenate those epitopes that have
a high likelihood of driving an effective
T cell response into a “string-of-beads”
format for insertion into a vaccine delivery vehicle. The process can be performed
in less than 24 h; the exact length of
time required for the analysis depends
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on whether comparisons have to be performed to other existing genomes and epitopes. Tools for carrying out the task have
been applied to the development of vaccine candidates for SARS,23 2009 H1N1
pandemic influenza,24 smallpox,25 and a
number of other emergent and biowarfare
agents, such as West Nile Virus, H. pylori
and Burkholderia.7,26-28 Most recently, the
tools were applied in May 2013 to the
design of a vaccine for H7N9, an emerging avian-origin influenza (Fig. 2).29 The
integration of epitope mapping into a
step-by-step vaccine design process makes
it possible to design vaccines in the shortest time possible once the DNA sequence
from the emerging infectious disease or
biowarfare pathogen is available. Should
errors later be found in the sequence, they
may impact one or two epitopes. For an
epitope-based string of beads vaccine,
the overall impact would be minimal,
since T cell epitopes are linear; in contrast, sequence variations may compromise the structural integrity of a whole
protein vaccine with negative effects on
immunogenicity.
How many epitopes? Available evidence
from animal studies suggests that the
number of vaccine components (epitopes)
required for full protection against disease
is a small and definable subset that can be
discovered using state-of-the-art computer
programs such as the ones described and
validated by EpiVax.30,31 We have proposed that any FastVax vaccine would
include a minimum of 100 broadly reactive T cell epitopes in several strings,
designed to induce multi-functional
immune responses that are essential for
protective immunity.32 Careful selection
of the vaccine components, comprising
epitopes covering most common HLA,
can provide greater than 99% coverage of
diverse human populations.33
Need for adjuvants? Currently, MF59
and AS03, both oil-in-water emulsions,
and virosome, a liposome formulation,
are three adjuvants licensed for use in
seasonal, pre-pandemic and pandemic
influenza vaccines. No influenza vaccines
containing adjuvant are FDA approved.
T cell epitope vaccine responses may be
enhanced through genetic immunization.34 DNA vaccines are self-adjuvanting
through co-encoded sequences, and thus
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many such vaccines do not incorporate
traditional adjuvants in their final formulation. A number of strategies that are currently being evaluated may improve DNA
vaccine potency for humans, including
use of more efficient promoters and codon
optimization, addition of traditional or
genetic adjuvants, electroporation and
intradermal delivery.35
Step two: Manufacturing and production. Reliable, reproducible methods for
producing vaccines are currently available.
The FastVax consortium favors DNA vaccines because production is scalable, the
vaccines are stable at room temperature,
manufacturing can be easily distributed
to different geographic locations, and the
production method is more rapid than
many other vaccine manufacturing technologies. Alternative scalable and rapid
production methods for accelerated vaccine production include plant-derived
vaccines, phage-based vaccines and
recombinant vaccines produced in cell
culture. Proteins produced using each of
these systems have been approved by the
FDA for use in humans.
Rapid production of DNA vaccines.
The initial vaccine sequence designed in
silico can be electronically provided to a
production facility, where a cassette representing the vaccine genetic construct(s)
is then synthesized and inserted into a
standardized DNA vaccine plasmid. A
cGMP seed lot of bacteria containing
the vaccine plasmid with cassetted payload can be rapidly produced and vialed
using existing SOPs for release and characterization assays. An initial manufacturing lot of plasmid vaccine would be
produced from the seed lot and used to
initiate safety studies. To reduce time to
produce sufficient vaccine product, multiple scale-up facilities could be located in
different regions of the US. Using current
methods of DNA vaccine development,
seed lot production would take one to
three weeks. Scale-up for DNA production is much more rapid than traditional
vaccine designs; only three to four weeks
would be required to produce one million
doses per facility. See below for discussion
of Biological Agents Research Defense
Agency (BARDA) appropriations for the
construction of distributed vaccine production facilities.
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The DNA vaccine delivery platform
and rational in silico design provide for
a strong safety profile. The DNA vaccine manufacturing process, particularly
the efficient and stringent release criteria,
allow for a highly pure and well-characterized final product. Rational design
permits in silico analysis of the vaccine
sequence for identification of potential
unfavorable immune responses including regulatory sequences or cross-reactive
immune responses. A fundamental principle of rapid biodefense vaccine production
is that safety and speed are paramount for
eliciting a protective immune response
prior to the epidemic.
Delivery vehicle. The bulk vaccine
product would then be coated onto premanufactured micro-needle patches that
provide direct delivery to the dermis, or
would be delivered using another skinbased method such as “scarification.” A
number of self-applied patch delivery systems have already been developed. These
would be optimal in bioterror and pandemic scenarios, because patches can be
pre-manufactured and stored in bulk and
do not require refrigeration for delivery or
trained practitioners for administration.36
Vaccination centers would not be required,
which would minimize transmission of
the biothreat organism between patients
and health care providers. Alternatively,
previously approved electroporation delivery methods37 could be used, though this
would take more time and increase the
need for vaccine administration personnel
training, leading to an escalation of the
vaccine administration expense and more
protracted timelines.
Step three: Clinical trials. While there
are no Phase III or FDA-approved DNA
vaccines, there are more than 30 Phase
II trials listed in clinicaltrials.gov. FDA
approval of a DNA vaccine appears to be
on the horizon, but until then, the FastVax
DNA vaccine may encounter an additional
FDA-associated barrier. Implementation
of a previously untested vaccine is only
possible after rapidly completing initial
clinical testing to the point that “emergency use authorization” can be invoked
by the Secretary of Health and Human
Services (HHS). In some biodefense scenarios, approximate correlates of protection may have been previously identified;
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such is the case with Lassa Fever, Ebola,
the encephaloviruses, and a number of
other “Category A, B and C” biodefense
pathogens. In some cases, correlates of
protection are unknown, and either an
antibody-focused or a T cell-driven vaccine may prove effective. Where antibodymediated immunity is critically important,
T cell-driven vaccines still merit attention
as potential adjuncts to more traditional
whole-antigen (B cell-driven) approaches,
since T cell help drives higher titer, higher
affinity antibody responses. Especially
in settings where challenge studies cannot be performed in advance of use in
humans, licensure may be possible by
means of the “Two Animal Rule” in lieu
of a human correlate. Rapid clinical testing can be achieved using existing commercial clinical research organizations and
clinical site networks such as the Medical
Countermeasures
Clinical
Studies
Network currently envisioned by ASPR/
BARDA. Emergency use authorization
approval can be based on achievement of
“correlates” such as induction of broadly
protective T cell or antibody responses,
provided an allowed Investigational New
Drug (IND) Application is in hand.
One problem facing T cell-driven vaccines that are designed to stimulate HLArestricted human immune responses is
that testing for correlates of immunity as
described in the “Two Animal Rule” may
not demonstrate the true efficacy of the
product. Thus alternative approaches may
need to be considered.
The MIMIC assay, a comprehensive
measurement of localized reactogenicity,
could be utilized for initial safety studies and to qualify release of the actual
vaccine intended for emergency use.38
Additionally, in pandemic response simulations, “mock up” or example vaccines (in
a specific DNA plasmid backbone) and
patch delivery system could be submitted
for approval by the FDA, and this formulation would be evaluated in the clinic for
immunogenicity that recapitulates the
influenza correlates of protective immunity already defined by CBER and EMA.
Correlates of protective immunity for currently approved influenza vaccines will not
serve as a basis for regulatory approval of
a DNA vaccine. The FDA would require
correlates to be determined for a new
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influenza vaccine and will not rely on
related, but different, vaccines already
approved. Advance trials will establish
correlates of protection for a FastVax
influenza vaccine to serve as a basis for
regulatory review in an emergency. In a
pandemic, a novel FastVax sequence composition might be rapidly tested in a small,
swiftly completed safety and immunogenicity trial, much like EMA precedence
for annual influenza vaccine updates.
Step four: Approval and emergency use
authorization. One means of obtaining
initial FDA review, experience and oversight for the FastVax vaccine-on-demand
system would be to firmly establish the
immunogenicity of an existing, clinicaltrial-ready DNA influenza virus vaccine
in a patch or scarification delivery system.
Demonstration that the vaccine candidate meets influenza correlates of protection criteria with an acceptable profile in
human trials would inform regulatory
review for products of similar composition,
much as current regulatory policy supports
annual marketing re-authorization despite
changes in influenza subunit vaccine composition (from trivalent to quadrivalent) to
reflect seasonal shifts and drifts.
Timely approval by the FDA to allow
distribution of product in response to a
rapidly emerging threat would require
close cooperation between the vaccine
manufacturer and the Agency. The manufacturer can assist by providing clinical safety and efficacy data for a variety
of vaccine products based on standardized vaccine platform, manufacturing,
specifications, operating procedures and
method of delivery. If the manufacturer
can establish predictable immunogenicity of epitopes in a demonstrated safe and
reproducible vaccine platform and rapidly
perform Phase I and Phase II trials establishing safety and immunogenicity in
terms of a surrogate endpoint that predicts
clinical benefit, the Agency may be able
to provide a rapid review and emergency
use allowance/authorization; release of the
vaccine would then be possible through
emergency use authorization by the HHS
Secretary.
Scale up. To reduce the time to vaccine
production, manufacturing sites could be
pre-inspected and maintained at a state of
operational readiness. While this would
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involve redundancy and higher costs, it
would allow for the rapid production and
scale-up of vaccines at any given moment.
Each site would need to utilize the same
manufacturing process to ensure consistency across vaccine batches, and entities
would need to be willing to share their
specific methodologies to harmonize an
approach. One site would create the master cell bank (MCB), and then generate
the manufacturer’s working cell bank
(MWCB) for distribution to all other
sites. In order to reduce production time
by two weeks, this step would be performed “at risk,” meaning MWCBs would
be distributed prior to the completion of
testing on either the MCB or MWCB.
Sequencing on the MCB could likely be
completed before the MWCB goes into
fermenter starters. Assuming that a dose
would constitute 0.2 mg of DNA vaccine
and that each site has several 240 L fermenters (either as back-ups or for parallel
growth), one million doses (200 g) per site
could be produced in a three- to four-week
period. BARDA recently invested hundreds of millions of dollars in distributed
influenza vaccine production; adapting
these facilities for DNA vaccine production would be an added but not insurmountable expense (as compared with the
initial investment).39
An in vitro assay like the MIMIC system could serve as a release characteristic
of the multi-site lots that would run in
parallel with the patch loading, preventing
a single problematic DNA vaccine batch
from impeding the release of patches generated with other batches. If the backbonehost system is proven to be rugged with
virtually any type of insert, a pilot run
would no longer be necessary. Conversely,
if the system is not shown to be rugged,
then pilot runs would be important, as
some inserts can greatly influence stability and growth characteristics. Such pilot
runs would need to be undertaken at
every facility, most likely with different
methods tested, to maximize the likelihood of determining the best method for
production.
Summary
A number of technological advances are
moving T cell-driven vaccines to the
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foreground with lessons applicable to
influenza T cell-driven vaccine development. Perhaps the most prominent
example of this new focus is the expanding use of T cell-driven immunotherapy
as an adjunct to cancer therapy. Many of
the barriers to effective T cell-driven vaccine development are being addressed and
surmounted in clinical cancer trials. For
example, dendritic-cell pulsing vaccines
using tumor antigens have moved into
clinical use.40,41 Outcomes of these types
of vaccination protocols have improved as
MHC class II epitopes (CD4 + T cell help)
were included42 and antibodies against
cytotoxic T lymphocyte antigen-4 (antiCTLA-4; see ref. 43) and other anti-T
regulatory cell (Treg) agents have been
added to the conditioning regimen.
Quite a few T cell-driven vaccines
are currently in human clinical trials
(reviewed by Gilbert in 2012; see ref.
44). While it is true that infectious disease T cell-driven vaccines have lagged
behind T cell-driven vaccines for cancer,
the regulatory pathway for T cell vaccines
is improving, since more than 250 cancer
vaccines that are based on T cell-driven
immune responses are in clinical trials.a
Furthermore, recent challenge studies
have shown that humoral immunity is not
required for protection against all human
pathogens. This was demonstrated in the
case of influenza, following vaccination of
study participants with a multi-antigen
vaccine. Following exposure to live influenza virus, two of 11 vaccinees and five of
11 control subjects developed laboratoryconfirmed influenza (symptoms plus virus
shedding). Symptoms of influenza were
less pronounced in the vaccinees and there
was a significant reduction in the number
of days of virus shedding in those vaccinees who developed influenza (mean
of 1.09 d in controls, 0.45 d in vaccinees,
p = 0.036)45,46 for a final efficacy of 60%,
which is better than many vaccines currently available.
This is a major milestone for T cell vaccines for infectious disease, as it is one of
the first vaccines to reach a Phase 2 clinical trial and none have reached Phase 3.
While one cannot directly extrapolate
from this trial nor the many cancer T
cell-driven immunotherapy trials to state
that the approach will work for all types
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of vaccines against infectious disease,
successful implementation of the T celldriven approach in a range of contexts
suggests that it is worth pursuing.
Immunome-mining (computational
immunology) tools have played a major
role in the design and development of T
cell-driven vaccines for infectious diseases.
The process was first termed “vaccinomics” by Brusic and Petrovsky in 2002,47
then “reverse vaccinology” by Rappuoli in
2003,48 and more recently, “immunomederived or genome-derived vaccine design”
by Pederson,49 De Groot and Martin,50
and Doytchinova, Taylor, and Flower.51
The concept behind these descriptors is
that a minimal set of antigens that induces
a competent immune response to a pathogen or neoplasm can be discovered using
immunoinformatics, and that administration of these epitopes in the right delivery
vehicle and with the correct adjuvant will
result in a degree of protection against
infection by the pathogen. In short, the
T cell-driven approach to developing
vaccines is based on these fundamental
principles: Payload + Adjuvant + Delivery
vehicle = Vaccine.
T cell-driven vaccines also offer some
significant advantages over conventional
vaccines for infectious diseases. For
example, despite strain-to-strain variation
at the protein level, immunoinformatics tools can be used to identify highly
conserved T cell epitopes that are immunogenic and broadly representative or universal, covering a wide range of variant
strains; our group has published results
for TB, HIV, smallpox, HCV and H.
pylori,16,52-58 and additional evidence can
be found in literature published by other
gene-to-vaccine researchers (e.g., Sette and
Newman, Brusic, Petrovsky, Reche, and
He). Concatenation of multiple epitopes,
either from a single organism or from multiple pathogens in a single delivery vehicle, has been shown to elicit broad-based
immune response directed at the epitopes
and is associated with improved efficacy
when compared with the whole organism
(lysate) in animal challenge studies.59,60
Furthermore, epitope-based vaccines
limit the antigenic load, diminishing
the need to manufacture and administer
large quantities of immunogen, much of
which is immunologically irrelevant. In an
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important advance for T cell-driven vaccines, new tools (e.g., JanusMatrix; see ref.
61) may enable vaccine developers to select
potent T effector epitopes, and to differentiate these from Treg-activating epitopes
and/or self-cross-reactive epitopes that
may lead to immunopathogenic responses
(Losikoff P, et al. Forthcoming).62-64
Over the past five years, the authors
of this report have advanced a number
of T cell-driven vaccines described to the
point of formulation and delivery studies. Vaccines for many of the high-priority biodefense pathogens and emerging
or re-emerging infectious diseases under
development are not currently available, and evidence that T cell-mediated
immune response is critically important
for protection against these pathogens is
emerging.43,65-69
Members of the FastVax consortium are well aware that there are many
obstacles to overcome before the proposed
“rapid response” or FastVax platform for
biodefense vaccines can be implemented.
Nonetheless, there is a critical national
need for an accelerated vaccine design,
development and production process
that can be accomplished in weeks, not
months, in the event of a serious infectious
disease outbreak or biowarfare attack. The
development of a rapid response to emerging infectious disease threats, using bestin-class technologies to provide a first
line of defense, will contribute to greater
biodefense preparedness and a significant
improvement in the ability of the US to
protect its citizens against pandemic infectious diseases. The need for new vaccines
for protecting against bioterror pathogens
and emerging infectious disease is great,
and we would argue that, for the reasons
cited above, the time to advance these vaccines to the clinic is now.
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Endnote

There are 276 clinical trials for “T cell
vaccines” currently reported at http://
www.cancer.gov/clinicaltrials/search.
a
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